Identification of Long Noncoding RNA Biomarkers for Hepatocellular Carcinoma Using Single-Sample Networks.

Publisher: Hindawi Pub. Co Country of Publication: United States NLM ID: 101600173 Publication Model: eCollection Cited Medium: Internet ISSN: 2314-6141 (Electronic) NLM ISO Abbreviation: Biomed Res Int Subsets: MEDLINE

Original Publication: New York, NY : Hindawi Pub. Co.

Gene Expression Regulation, Neoplastic*; Biomarkers, Tumor/*genetics ; Carcinoma, Hepatocellular/*genetics ; Liver Neoplasms/*genetics ; RNA, Long Noncoding/*genetics; Algorithms ; Biomarkers ; Carcinoma, Hepatocellular/mortality ; Female ; Gene Expression Profiling ; Humans ; Kaplan-Meier Estimate ; Liver Neoplasms/mortality ; Male ; Prognosis ; Proportional Hazards Models ; RNA-Seq ; ROC Curve ; Regression Analysis ; Risk

Objective: Many studies have found that long noncoding RNAs (lncRNAs) are differentially expressed in hepatocellular carcinoma (HCC) and closely associated with the occurrence and prognosis of HCC. Since patients with HCC are usually diagnosed in late stages, more effective biomarkers for early diagnosis and prognostic prediction are in urgent need.
Methods: The RNA-seq data of liver hepatocellular carcinoma (LIHC) were downloaded from The Cancer Genome Atlas (TCGA). Differentially expressed lncRNAs and mRNAs were obtained using the edgeR package. The single-sample networks of the 371 tumor samples were constructed to identify the candidate lncRNA biomarkers. Univariate Cox regression analysis was performed to further select the potential lncRNA biomarkers. By multivariate Cox regression analysis, a 3-lncRNA-based risk score model was established on the training set. Then, the survival prediction ability of the 3-lncRNA-based risk score model was evaluated on the testing set and the entire set. Function enrichment analyses were performed using Metascape.
Results: Three lncRNAs (RP11-150O12.3, RP11-187E13.1, and RP13-143G15.4) were identified as the potential lncRNA biomarkers for LIHC. The 3-lncRNA-based risk model had a good survival prediction ability for the patients with LIHC. Multivariate Cox regression analysis proved that the 3-lncRNA-based risk score was an independent predictor for the survival prediction of patients with LIHC. Function enrichment analysis indicated that the three lncRNAs may be associated with LIHC via their involvement in many known cancer-associated biological functions.
Conclusion: This study could provide novel insights to identify lncRNA biomarkers for LIHC at a molecular network level.
Competing Interests: The authors declare that there is no conflict of interest regarding the publication of this paper.
(Copyright © 2020 Xiaoqing Yu et al.)

Am J Surg. 1997 Apr;173(4):358-65. (PMID: 9136797)
PLoS Genet. 2013 Jun;9(6):e1003569. (PMID: 23818866)
Nat Cell Biol. 2003 Dec;5(12):1029-33. (PMID: 14647295)
Gastroenterology. 2012 May;142(6):1264-1273.e1. (PMID: 22537432)
Brief Bioinform. 2017 Jul 1;18(4):558-576. (PMID: 27345524)
Cancer Chemother Pharmacol. 2012 May;69(5):1173-80. (PMID: 22237956)
Cancer Med. 2020 Jun;9(12):4290-4298. (PMID: 32311840)
Nature. 2001 Feb 15;409(6822):860-921. (PMID: 11237011)
Oncogene. 2016 Mar 24;35(12):1575-84. (PMID: 26073087)
Biomark Res. 2013 Feb 05;1(1):10. (PMID: 24252133)
Med Sci Monit. 2016 Oct 11;22:3647-3657. (PMID: 27727196)
Med Res Rev. 2014 May;34(3):455-78. (PMID: 23775602)
Oncotarget. 2017 Apr 28;8(35):58699-58708. (PMID: 28938589)
J Mol Cell Biol. 2015 Jun;7(3):231-41. (PMID: 25917597)
Nat Rev Genet. 2011 Jan;12(1):56-68. (PMID: 21164525)
Clin Liver Dis. 2015 May;19(2):223-38. (PMID: 25921660)
Nat Rev Genet. 2009 Mar;10(3):155-9. (PMID: 19188922)
J Theor Biol. 2014 Dec 7;362:35-43. (PMID: 24931676)
Asian Pac J Cancer Prev. 2015;16(9):3595-604. (PMID: 25987009)
Int J Oncol. 2016 Apr;48(4):1590-8. (PMID: 26892468)
Biomark Med. 2018 Mar;12(3):205-215. (PMID: 29424557)
Int J Mol Sci. 2018 Mar 20;19(3):. (PMID: 29558460)
J Hepatol. 2017 Sep;67(3):603-618. (PMID: 28438689)
J Clin Gastroenterol. 2002 Nov-Dec;35(5 Suppl 2):S72-8. (PMID: 12394209)
Oncologist. 2010;15 Suppl 4:5-13. (PMID: 21115576)
PeerJ. 2017 Jul 18;5:e3575. (PMID: 28729955)
Nature. 1961 Dec 30;192:1227-32. (PMID: 13882203)
Onco Targets Ther. 2016 Sep 19;9:5701-5711. (PMID: 27703371)
Eur J Gastroenterol Hepatol. 2010 Sep;22(9):1099-105. (PMID: 20177386)
Nat Commun. 2016 Aug 24;7:12598. (PMID: 27553854)
Oncotarget. 2017 Mar 7;8(10):16811-16828. (PMID: 28187432)
Nucleic Acids Res. 2016 Dec 15;44(22):e164. (PMID: 27596597)
Asian Pac J Cancer Prev. 2013;14(9):4953-60. (PMID: 24175758)
Mol Syst Biol. 2012 Jan 17;8:565. (PMID: 22252388)
Brief Funct Genomics. 2015 Mar;14(2):115-29. (PMID: 25212482)
J Am Med Inform Assoc. 2012 Mar-Apr;19(2):241-8. (PMID: 22190040)
Mol Neurobiol. 2018 May;55(5):3684-3697. (PMID: 28527107)
Nat Commun. 2014 Dec 19;5:5812. (PMID: 25524025)
Nat Rev Clin Oncol. 2015 Jul;12(7):408-24. (PMID: 26054909)
Nat Commun. 2019 Apr 3;10(1):1523. (PMID: 30944313)
Oncol Rep. 2017 Nov;38(5):2607-2618. (PMID: 28901457)
Front Genet. 2015 Jan 26;6:2. (PMID: 25674102)
Genes Dev. 2009 Jul 1;23(13):1494-504. (PMID: 19571179)
Cancer Res. 2019 May 15;79(10):2536-2548. (PMID: 30940658)
Cancer Res. 2011 Nov 15;71(22):7038-47. (PMID: 22006999)
Cell Res. 2012 Mar;22(3):565-80. (PMID: 21894192)
World J Hepatol. 2015 Dec 8;7(28):2781-91. (PMID: 26668690)

0 (Biomarkers)
0 (Biomarkers, Tumor)
0 (RNA, Long Noncoding)

Date Created: 20201210 Date Completed: 20210608 Latest Revision: 20220418

20240104

PMC7700720

10.1155/2020/8579651

33299877